Composite endpoints are commonly used as the primary measure of efficacy in heart failure clinical trials to assess the overall treatment effect and to increase the efficiency of trials.
INTRODUCTION
Composite endpoints are increasingly used as primary efficacy measures in heart failure clinical trials (Supplemental Appendix Table 1) 1 to provide a comprehensive picture of the treatment effect, and to improve trial efficiency by increasing the event rate and reducing the required sample size. They have advantages and disadvantages (Table 1) , [1] [2] [3] [4] but composite endpoints are generally accepted by academics, clinicians, and regulators when the components are well-defined, specific to the key objective of interest, and broadly congruent in regards to treatment effect. They are problematic when the overall effect suggests no benefit, or even harm, in one or more components.
The adoption of evidence-based therapies has reduced event rates for well-established composites (e.g., all-cause mortality plus cardiovascular hospitalization; cardiovascular death plus heart failure hospitalization). Thus, large studies with long follow-up are still needed in modern trials to accrue a sufficient number of events for adequate statistical power. These studies require substantial investment from funders (e.g., public or industry sources) who must decide whether to commit significant funds when there is a real risk that the therapy will be ineffective. Industry investment in cardiovascular drug development has been decreasing, perhaps in part because of these reasons, 5;6 and cardiovascular disease is no longer one of the top ten therapeutic areas for research and development. 7 It is a matter of debate whether the composite of cardiovascular mortality or heart failure hospitalization is the most meaningful and clinically relevant endpoint. New endpoints (e.g., novel clinical composites, functional measures, or patient reported outcomes) or analytic methodologies (e.g., recurrent event analyses, responder analyses) might serve the dual purpose 5 of more accurately reflecting the modern heart failure patient's disease burden and improving trial efficiency. However, confirmation of their validity is needed before they can achieve widespread acceptance.
The Cardiovascular Round Table (CRT) of the European Society of Cardiology (ESC) convened a two-day workshop to explore how existing and innovative composite endpoints can be leveraged to advance the conduct of heart failure clinical trials and, ultimately, patient care.
Workshop participants identified five qualities that should characterize composite endpoints in heart failure clinical trials (Table 2 ). This paper summarizes the key insights and discussions, suggests approaches for using composite endpoints, and identifies knowledge gaps that need to be addressed by further research.
OVERVIEW OF COMPOSITE ENDPOINTS IN HEART FAILURE TRIALS

Fatal and Non-Fatal Composite Clinical Outcomes
All-cause assessments of fatal and non-fatal outcomes (e.g., all-cause mortality plus allcause hospitalization) reflect an intervention's net benefit. Since a single intervention is unlikely to reduce all modes of death or causes of hospitalization, a significant reduction in an all-cause composite endpoint can be interpreted to indicate that the intervention reduced the major causes of death or hospitalization (usually cardiovascular in heart failure trials) without significant adverse effects. Owing in part to this experience, heart failure trials are often now designed with causespecific composite endpoints (e.g., cardiovascular mortality or heart failure hospitalization).
Cause-specific endpoints reflect a more precise evaluation of an intervention's expected effect, since it is unlikely that a cardiovascular drug will reduce non-cardiovascular causes of death (e.g., cancer, accidents Reporting the individual components of composite endpoints is important to examine whether or not they are concordant, but non-fatal endpoints should not be analyzed independently because of the problem of competing risks. 12 Composite endpoints can solve this dilemma if they include both fatal and non-fatal events. However, analyzing fatal and non-fatal events in a composite endpoint can be problematic because these events differ in their importance. The least serious events (i.e., hospitalizations in heart failure trials, non-fatal myocardial infarctions in acute coronary syndrome trials) usually occur earlier than more serious 8 events (i.e. death). Time-to-event analysis focuses on the first event. Thus, composite endpoints are often driven by the least serious component, 13 which decreases the relevance (not confidence) of any finding. For example, in the Systolic Heart Failure Treatment with the If Inhibitor Ivabradine Trial (SHIFT) study, the primary endpoint was a composite of cardiovascular death or hospital admission for worsening heart failure. 14 Ivabradine reduced the risk of the primary endpoint compared with placebo in patients with a heart rate ≥70 beats per minute (HR 0.82, CI 0.75-0.90, p<0.0001), mainly driven by a reduction in heart failure hospitalizations (16% vs.
21%, HR 0.74, CI 0.66-0.83, p<0.0001) with no effect on cardiovascular mortality (14% vs.
15%, HR 0.91, CI 0.80-1.03, p=0.13). 14 The European Medicines Agency (EMA) approved ivabradine, but only for patients with heart rates above 75 beats per minute where a possible nominal reduction in overall mortality was observed. 15 Food and Drug Administration (FDA) approval was recently granted for a reduction in heart failure hospitalization in patients with a heart rate ≥70 beats per minute. Based on results from the Valsartan Heart Failure Trial (ValHeFT), valsartan was approved by the FDA to reduce hospitalization for heart failure, with no indication for improvement in mortality because it reduced only one of the two primary endpoints: 1) all-cause mortality (relative risk 1.02, CI 0.88-1.18, p=0.80) and 2) the composite of all-cause mortality or cardiac arrest with resuscitation, hospitalization for heart failure, or administration of intravenous inotropes or vasodilators for ≥4 hours without hospitalization (relative risk 0.87, CI 0.77-0.97, p=0.009). The beneficial effect of valsartan on the latter was driven by a reduction in heart failure hospitalization. 16 Statistical methods to weight outcomes according to severity have been proposed in heart failure and other disease states. [17] [18] [19] [20] [21] [22] However, these approaches are limited by lack of consensus on the relative weighting of events and inconsistency across studies.
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These examples underscore the importance of limiting composites to include events that are clinically meaningful and considered to be modifiable. It is highly recommended that regulatory agencies be involved early in the process of constructing composite endpoints for use in pivotal trials.
Clinical Status Composite Endpoints
In chronic conditions such as heart failure, mortality is not the only meaningful efficacy 
FUNCTIONAL ENDPOINTS
Most clinicians agree that functional impairment is a primary concern for patients with heart failure. For some patients, improved functional status or quality of life is of greater importance than longevity. 24;25 Patients are surviving longer with heart failure because of therapeutic advances, 31 so assessing functional status may be of even greater importance in this era of improved survival. The primary goal of considering novel composite endpoints that include functional status or patient reported symptom measures is to identify treatments that improve important aspects of patient well-being beyond survival. However, few, if any, cardiovascular drugs have been approved on the basis of improved functional status alone.
Regulators have been cautious about functional-status endpoints in cardiovascular clinical trials because of agents that improved exercise tolerance but increased mortality in large trials (e.g., flosequinan). 32 The problem of defining a clinically meaningful change in exercise time (or 11 other measure of functional status) also contributes to the uncertainty about the value of this endpoint.
A clinically meaningful improvement in functional status may lead to approval of a new therapeutic agent, provided that an adequate margin of safety can be assured. 1 A stringent margin for excluding an adverse effect on mortality would likely be required in a trial using a functional primary endpoint. Thus, efficiencies gained by using novel composites may be offset
by the need to demonstrate safety, since studies would still need to be large and long enough to rule out an increased risk of mortality (at some threshold level acceptable to regulatory agencies)
or provide reasonable assurance of a neutral effect on mortality. Finally, another important consideration is the health technology assessment of new drugs after regulatory approval. Even if an endpoint such as 6-minute walk distance were accepted by regulators, it is uncertain whether payers would view it as a worthwhile endpoint.
Research would need to validate the level of increased exercise tolerance that was cost-effective and had a societal benefit.
Role of Adaptive Licensing
In 2007, EMA described its openness to innovative drug development approaches. 37 One such initiative is the Pilot Project on Adaptive Licensing. 38 Adaptive licensing involves an authorized limited indication followed by "iterative phases of evidence gathering and progressive licensing adaptations concerning both the authorized indication and the potential further therapeutic uses of the drug". 38 With adaptive licensing, a drug could be approved based on improvement in a well-defined functional endpoint within a rigorously conducted clinical trial.
After licensing, post-authorization efficacy and safety studies would be required. [38] [39] [40] This process fulfils the goal of accelerating patient access to new drugs, while providing a mechanism for collecting safety data. Functional status or patient-reported symptom endpoints could have a role in adaptive licensing, but past experiences in heart failure where initially promising drugs have later been found harmful (e.g., ibopamine, flosequinan) emphasize the need to pursue this approach cautiously. Many issues have been identified with this approach. First, it is uncertain 13 if a relatively short-term trial assessing a functional endpoint will accrue a sufficient number of events to provide early estimates of safety prior to granting an adaptive license. Additionally, the safety margin for excluding excess risk needs to be defined and achieving harmonization among regulatory bodies could be problematic. Presumably, the acceptable safety margin could vary by patient population, severity of illness, or the pre-test probability of risk in the context of the mechanism of action of the drug or device; thus, safety estimates should account for this variation. On the other hand, the adaptive approval process aims to accrue pharmacovigilance data in the early phase of marketing through registries, thereby monitoring the real-life use and adverse event rates of the drugs approved with this regulatory pathway. 41 Conducting randomized clinical trials after a drug is marketed and available to patients is more difficult than pre-approval from the standpoint of subject recruitment and retention. All patients receiving the drug could be followed in a registry for safety, but the results of observational studies are less reliable because of the potential for bias. The current system is not optimally designed to allow regulators to enforce withdrawal of adaptive licences if the sponsor does not uphold the requirements of the licence (e.g., follow-up trials are not completed, a concerning safety signal emerges but falls short of crossing pre-defined margins of licence withdrawal, safety trials are poorly designed), particularly in the European Union where decisions to withdraw drugs are made by each member state. One approach would be to apply adaptive licensing only to severely ill patients where the balance of risks and benefits might be more favourable. However, once marketed, restrictions on use according to patient severity will be difficult to enforce.
STATISTICAL CONSIDERATIONS: NEW ANALYTIC METHODS
Recurrent Event Analyses
Heart failure is a chronic disease, typically characterized by repeat hospitalizations as a patient's condition progressively worsens. Several factors have contributed to an interest in analysing recurrent events in heart failure trials. 42 Hospitalization is the major contributor to the overall cost of heart failure care, 43 which has led to targeted interventions to reduce readmissions. 44;45 Therefore, data describing an intervention's effect on recurrent events is highly clinically relevant. Importantly, restricting analyses to first events incompletely represents the patient's overall burden of disease, since first events account for only half of the total number of heart failure hospitalizations in major clinical trials. [46] [47] [48] [49] Several approaches to recurrent event analyses have been tested using major heart failure trial datasets. [46] [47] [48] [49] [50] [51] All have limitations, as complex assumptions are made in determining the study sample size and in the statistical modelling. 52 One concern is overestimation of the treatment effect, 48 Importantly, study power can be substantially reduced in a responder analysis when a continuous outcome measure is dichotomized. 59 Responder analyses might be useful in phase I and II trials to help inform phase III designs and patient selection criteria; however, many well-known examples exist where favorable phase II results did not translate into improved outcome in phase III. 60 Therefore, cautious interpretation of phase II results used for this purpose is advised. On the other hand, if efficacy is demonstrated using traditional methods, responder analyses can be performed secondarily to characterize the clinical relevance of the effect and to evaluate the potential for hyper-responders (in cardiac resynchronization therapy trials often called super-responders), non-responders, or patients who experience harm. Signals of efficacy or harm observed in subgroups are far from definitive, but they can generate new hypotheses for testing in adequately powered studies within the specific population that appeared to have the greatest treatment effect. Assessing heterogeneity of benefit or net benefit, balancing benefit and harm, using subgroups based on a risk score has been proposed as a more powerful approach to subgroup analysis. 61;62 Responder analyses are also of interest to support health technology assessment.
However, it is critical to acknowledge the limitations of these analyses to avoid over interpretation of the data.
CONCLUSION
The changing landscape for heart failure clinical trials has created an important opportunity to learn from past successes (and failures) and shape future approaches. The use of traditional composite endpoints has yielded many highly effective therapies, and the approach should not be abandoned. However, the overall health burden from heart failure on patients is broader than hospitalizations and death, and it will be important to conduct trials that reflect endpoints important to patients 35 (and payers). Further, the declining resources for conducting larger, longer, and more costly trials is a reality that cannot be ignored. 5 Composites that reflect both clinical status and traditional "hard" events, new analytic methodologies to assess recurrent events, and renewed efforts to assess changes in functional status (without ignoring safety) are areas of both interest and uncertainty that will benefit from additional research (Table 3) .
Ongoing trials will provide more insight into the strengths and weaknesses of these approaches and inform future directions in heart failure research. Time to confirmed cardiovascular death through 180 days and time to worsening heart failure through 5 days (also considering death), with all-cause mortality through 180 days pre-specified as a safety endpoint.
TRUE-HF 90
Two primary efficacy endpoints: 1) improvement in a hierarchical clinical composite endpoint (assessed at 6, 24, and 48 hours after start of study drug) including patient global assessment of symptomatic improvement, lack of improvement, or worsening; persistent or worsening heart failure requiring pre-specified mechanical or pharmacologic interventions, and all-cause death; 2) freedom from cardiovascular death throughout the duration of the trial. AUC = area under the curve; CV = cardiovascular; HF = heart failure; VAS = visual analog scale
